To date, only serum glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase L-1 (UCHL1) tests have been approved as biomarkers for mTBI by the United States Food and Drug Administration [11]. The gene discussed is GFAP; the disease is concussion.